Skip to content

Study · Randomized controlled trial · n = 20 · 2022

3 results

Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.

Valenzuela-Vallejo L, Chrysafi P, Bello-Ramos J, Bsata S, Mantzoros CS

Metabolism: clinical and experimental11 Jun 2022Cited by 22 (Europe PMC)

PMID35700837 (opens in a new tab)PMCIDPMC11426964 (opens in a new tab)DOI10.1016/j.metabol.2022.155237 (opens in a new tab)PepBankPUB-35700837
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with obesity, 5 weeks of liraglutide did not change circulating total GDF-15 despite significant changes in body weight.

    In plain wordsIn adults with obesity, liraglutide did not change the body's own total GDF-15 levels, even though body weight changed.

    Peptide
    Liraglutide
    Outcome
    No significant changeTotal GDF-15 level
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    0.6 mg/day rising to 3.0 mg/day · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    Despite significant changes in body weight, total and intact GDF-15 were not altered in response to liraglutide or lorcaserin treatment in subjects with obesity.
    1 context sentence
    Summary · context
    a randomized, double-blinded, cross-over trial of liraglutide and placebo administration for 5 weeks in subjects with obesity (n = 20; BMI = 35.6 ± 5.9 kg/m2), in escalating doses starting at 0.6 mg/day on week 1 and increased every week, up to the highest dose of 3.0 mg/day during week 5
  2. 02HumanRandomized controlled trialMechanism

    In adults with obesity, 5 weeks of liraglutide did not change circulating intact GDF-15 despite significant changes in body weight.

    In plain wordsIn adults with obesity, liraglutide did not change the body's own intact GDF-15 levels, even though body weight changed.

    Peptide
    Liraglutide
    Outcome
    No significant changeIntact GDF-15 level
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    0.6 mg/day rising to 3.0 mg/day · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    Despite significant changes in body weight, total and intact GDF-15 were not altered in response to liraglutide or lorcaserin treatment in subjects with obesity.
    1 context sentence
    Summary · context
    a randomized, double-blinded, cross-over trial of liraglutide and placebo administration for 5 weeks in subjects with obesity (n = 20; BMI = 35.6 ± 5.9 kg/m2), in escalating doses starting at 0.6 mg/day on week 1 and increased every week, up to the highest dose of 3.0 mg/day during week 5
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 5 weeks of liraglutide led to significant weight loss.

    In plain wordsIn adults with obesity, body weight fell during 5 weeks of liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 20

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6 mg/day rising to 3.0 mg/day · 5 weeksAs given in this study (human).

    Source sentences

    Title
    Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.
    2 context sentences
    Summary · context
    Despite significant changes in body weight, total and intact GDF-15 were not altered in response to liraglutide or lorcaserin treatment in subjects with obesity.
    Summary · context
    a randomized, double-blinded, cross-over trial of liraglutide and placebo administration for 5 weeks in subjects with obesity (n = 20; BMI = 35.6 ± 5.9 kg/m2), in escalating doses starting at 0.6 mg/day on week 1 and increased every week, up to the highest dose of 3.0 mg/day during week 5

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.